Acquisitions (Tables)

12 Months Ended

Dec. 31, 2016

Schedule of Book Value of Net Assets Under Common Control

In connection with the December 2016 Acquisition we acquired the following:



Cost investments ⁽¹⁾	$	2.1
Equity method investments ⁽²⁾	39.9
December 2016 Acquisition	$	42.0


⁽¹⁾	$2.1 million purchase price of 1.0% in Cleopatra.

In connection with the October 2016 Acquisition, we acquired net assets under common control and recorded at their historical carrying value as follows:



Equity method investments ^{(1) (2)}	$	54.3
October 2016 Acquisition	$	54.3


⁽¹⁾	$51.3 million historical carrying value of 20.0% additional interest in Mars contributed by SPLC.


⁽²⁾	$3.0 million historical carrying value of 49.0% interest in Odyssey contributed by SOPUS.

In connection with the November 2015 Acquisition we acquired historical carrying value of net assets under common control which is included in our consolidated balance sheet, as follows:



Property, plant and equipment, net⁽¹⁾	$	95.2
Asset retirement obligation⁽²⁾	(1.3		)
November 2015 Acquisition	$	93.9


⁽¹⁾	Historical carrying value of property, plant and equipment, net contributed by SPLC.


⁽²⁾	Historical carrying value of asset retirement obligation assumed by us.

In connection with the May 2016 Acquisition, we acquired historical carrying value of net assets under common control as follows:



Cost investments⁽¹⁾	$	5.2
Partners' capital⁽²⁾	87.0
May 2016 Acquisition	$	92.2


⁽¹⁾	Historical carrying value of 3.0% additional interest in Colonial contributed by SPLC.


⁽²⁾	Historical carrying value of 30.0% additional interest in Zydeco from SPLC’s noncontrolling interest.

Schedule of Financial Position and Results of Operations

In connection with the May 2015 Acquisition we acquired historical carrying value of net assets under common control as follows:



Cost investments ⁽¹⁾	$	2.5
Partners' capital ⁽²⁾	52.9
May 2015 Acquisition	$	55.4


⁽¹⁾	Historical carrying value of 1.388% additional interest in Colonial contributed by SPLC.


⁽²⁾	Historical carrying value of 19.5% additional interest in Zydeco from SPLC’s noncontrolling interest.